person
as of 2026-07-01Rishi Kakar, MD
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
4 publications · 1 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Innovative Clinical Research, Inc.
Roles
Principal Investigator, Author
KOL signal
8
Publications
4 (1 high-value)
Trial investigator
no
Publishes on
2 drugs
Trials led
1
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
NCT02008773Phase 2Completed
Publications & congress
4
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet (London, England) · 2024 · high-value
Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2026
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelberg, Germany) · 2025
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelberg, Germany) · 2024
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR